Vanguard Group Inc Sigilon Therapeutics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.48 - $0.86 $26,289 - $47,102	54,770 Added 22.25%	300,912 $152,000
Q2 2022 Aug 12, 2022	SELL	$0.74 - $1.64 $47,626 - $105,550	-64,360 Reduced 20.73%	246,142 $204,000
Q1 2022 May 13, 2022	SELL	$1.24 - $3.03 $271,630 - $663,742	-219,057 Reduced 41.37%	310,502 $456,000
Q4 2021 Feb 14, 2022	BUY	$2.58 - $6.13 $326,050 - $774,684	126,376 Added 31.34%	529,559 $1.46 Million
Q3 2021 Nov 12, 2021	BUY	$4.42 - $10.61 $200,561 - $481,439	45,376 Added 12.68%	403,183 $2.28 Million
Q2 2021 Aug 13, 2021	BUY	$9.15 - $20.17 $3.27 Million - $7.22 Million	357,807 New	357,807 $3.84 Million

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.